N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 50,000 shares at $24.07 ($1.2M) on 2023-09-07, disclosed to the SEC on 2023-09-08.
Open-market sale of $1.2M CERE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |